Schizophrenia
Conditions
Brief summary
This project will result in the development of a personalized intervention strategy to improve motivation for treatment engagement and functional outcomes in individuals with a recent onset of schizophrenia. Motivational impairment is arguably the single most important factor that determines a patient's ability to engage in and adhere to effective treatment. In our study, sixty participants will be enrolled in a randomized controlled trial comparing the feasibility and tolerability of two types of motivational interventions (Daily Goals or PRIME), and a neuroplasticity-based cognitive training program. Participants are randomized to either receive Daily Goals or PRIME for 8 weeks, after which, both conditions will also receive an 8-week course of cognitive training delivered via iPads. Participants will undergo pre/post-testing and a 6-month follow-up to determine feasibility and efficacy of the interventions. By enhancing motivation, schizophrenia patients would be able to engage more fully with treatment and develop full and productive lives. This study may also pave the way forward for other health conditions in which motivational impairments impede health outcomes. All assessments will be conducted at the University of California, San Francisco; however, we offer some assessments to be done remotely.
Interventions
BEHAVIORALPRIME
Mobile application designed to improve psychosocial functioning and motivational deficits
BEHAVIORALCognitive Training
Auditory processing, verbal learning, memory, processing speed, and social cognition
Sponsors
University of California, San Francisco
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
14 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. * Onset of diagnosis within 5 years. * 14-30 years old. * Clinically stable (outpatient status for 1 month and stable dose of medication for 1 month). * Good general health
Exclusion criteria
* Substance dependence within the past 12 months, * Current substance abuse, * No history of neurological disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Psychosocial functioning | past 30 days | Work status, work performance, social status, social performance, health status, health performance |
Countries
United States
Outcome results
None listed